Monthly Update: Oncologic, Endocrine & Metabolic: What's new about new tubulin/microtubules binding agents?
- 1 August 1995
- journal article
- Published by Informa Healthcare in Expert Opinion on Investigational Drugs
- Vol. 4 (8) , 771-775
- https://doi.org/10.1517/13543784.4.8.771
Abstract
Pharmaceutical research on new anticancer drugs continues in two directions: a ‘prospective’ one involving the selection of compounds acting on ‘new’ biological targets; and a ‘conservative’ one involving the selection of chemotherapeutic agents acting on ‘validated’ targets. Clinical interest in paclitaxel (Taxol™) and docetaxel (Taxotere™) has led to a reactivation of research on agents that bind tubulin/microtubules. Several new antimitotic compounds were presented at the American Association for Cancer Research meeting in Toronto, last April.Keywords
This publication has 5 references indexed in Scilit:
- Structure of Curacin A, a Novel Antimitotic, Antiproliferative and Brine Shrimp Toxic Natural Product from the Marine Cyanobacterium Lyngbya majusculaThe Journal of Organic Chemistry, 1994
- Neural Computing in Cancer Drug Development: Predicting Mechanism of ActionScience, 1992
- Total synthesis of halichondrin B and norhalichondrin BJournal of the American Chemical Society, 1992
- Natural products which interact with tubulin in the vinca domain: Maytansine, rhizoxin, phomopsin a, dolastatins 10 and 15 and halichondrin BPharmacology & Therapeutics, 1992
- Taxol-dependent mutants of Chinese hamster ovary cells with alterations in alpha- and beta-tubulin.The Journal of cell biology, 1986